Background of the FDA's Accelerated Approval of Ikervia, the First Dual-Action Drug

Iqirvo (Iqirvo, active ingredient: elafibranor), Ipsen's treatment for Primary Biliary Cholangitis (PBC), received Accelerated Approval from the U.S. Food and Drug Administration (FDA) on June 10, 2024. This drug is the first dual PPAR agonist that simultaneously acts on peroxisome proliferator-activated receptor alpha and delta (PPARα/δ), which regulate bile acid synthesis and inflammatory responses. In the Phase 3 ELATIVE study, it demonstrated a significant reduction in Alkaline Phosphatase (ALP) levels in adult patients who were unresponsive to or intolerant of ursodeoxycholic acid (UDCA), the existing first-line treatment, thereby preventing bile duct damage. This has significant clinical implications, as it offers new hope for PBC patients who previously had limited treatment options, by improving liver function and relieving pruritus.

Securing Long-Term Efficacy through the Latest Phase 3b Success

Ikervia has not only achieved approval but has also further demonstrated its long-term efficacy through the ELSPIRE trial, an additional Phase 3b study released in July 2026. According to the results of this trial, 85% of patients who received Ikervia achieved normalization of ALP, a key indicator of liver damage, compared to 23% in the placebo group, demonstrating overwhelming statistical significance. This strong data will undoubtedly serve as crucial confirmatory evidence for Ikervia to transition from its current accelerated approval status to full approval in the future. The medical community believes that Ikervia will not only inhibit the progression of the disease but also become a fundamental treatment that directly improves the quality of life for patients.

Market Restructuring with the Withdrawal of Competing Drugs and a Shift to PPAR Agonists

Currently, the global market for primary biliary cholangitis treatment is undergoing a rapid generational shift and a change in the competitive landscape. Intercept's Ocaliva, an FXR agonist that previously dominated the secondary treatment market, voluntarily withdrew from the U.S. market in September 2025 due to concerns about side effects and negative opinions from the Advisory Committee (AdComm). As a result, the prescription pattern has shifted completely to the PPAR agonist class, which has a better safety profile, and Ikervia is reaping the benefits. Although Livdelzi, a PPAR agonist from CymaBay, acquired by Gilead Sciences, is another competitor, Ikervia's early market entry and strong clinical data give it an advantage in securing an initial market lead.

Successful License Partnership and Achievement of Financial Milestones

Ikervia is an asset that Ipsen acquired from GENFIT, a French biotech company, in December 2021, and it is a prime example of a successful commercial partnership between the two companies. At the time of the agreement, Ipsen made an upfront payment of 120 million euros and invested in an 8% equity stake in GENFIT, and agreed to pay up to 360 million euros in additional milestones based on future performance. Ikervia has seen explosive prescription growth since its launch, exceeding cumulative net sales of 200 million dollars in early 2026, triggering a financial milestone of 20 million dollars to GENFIT. The activation of a royalty structure of up to 20% of sales is also creating a win-win situation for both the developer and the commercial partner, setting a model example for biotech licensing deals.